|
Re: Endocrine News
|
6
|
Resverlogix Corp.
|
Jun 02, 2017 06:46AM
|
|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 18, 2018 02:35PM
|
|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 18, 2018 02:54PM
|
|
Re: Endocyte vs Zenith
|
7
|
Zenith Epigenetics
|
Sep 14, 2018 11:21AM
|
|
Re: Enrichment
|
11
|
Resverlogix Corp.
|
Jul 12, 2020 09:01AM
|
|
Re: Entertainment During Wait
|
2
|
Resverlogix Corp.
|
Aug 25, 2017 02:04PM
|
|
Re: Entresto VS Apabetalone
|
1
|
Resverlogix Corp.
|
Mar 02, 2020 12:24PM
|
|
Re: Enzalutamide effective in non-metastatic prostate cancer
|
5
|
Zenith Epigenetics
|
Jun 29, 2018 10:51AM
|
|
Re: Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
|
5
|
Resverlogix Corp.
|
Jun 09, 2020 08:49PM
|
|
Re: Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
|
5
|
Resverlogix Corp.
|
Jun 10, 2020 08:49AM
|
|
Re: Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
|
1
|
Resverlogix Corp.
|
Jun 10, 2020 09:33AM
|
|
Re: Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020
|
7
|
Resverlogix Corp.
|
Jul 29, 2020 09:57AM
|
|
Re: Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020
|
6
|
Resverlogix Corp.
|
Jul 29, 2020 10:06AM
|
|
Re: Epigenetic Therapeutic Targets Virtual Summit Presentation July 28, 2020
|
4
|
Resverlogix Corp.
|
Jul 29, 2020 10:22AM
|
|
Re: Epigenetics and Coronavirus
|
4
|
Resverlogix Corp.
|
Mar 23, 2020 03:25PM
|
|
Re: Epigenetics article,...
|
2
|
Resverlogix Corp.
|
Jun 04, 2019 10:53PM
|
|
Re: Epigenetics article,...
|
|
Resverlogix Corp.
|
Jun 05, 2019 02:24PM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
3
|
Resverlogix Corp.
|
Jan 17, 2016 09:54PM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
8
|
Resverlogix Corp.
|
Jan 18, 2016 01:35PM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
10
|
Resverlogix Corp.
|
Jan 18, 2016 06:22PM
|
